Navigating the ADC Development Pathway
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges....
Continue Reading
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges....
Continue Reading
Multi-target drugs targeting GLP1R/GIPR/GCGR have demonstrated superior efficacy for weight loss and glycemic control compared to single-target GLP1R drugs. However,...
Continue Reading
Gouty arthritis is a common, painful inflammatory condition characterized by the deposition of monosodium urate (MSU) crystals in joints. This...
Continue Reading
RNA therapeutics can target specific mRNAs with high specificity, making them advantageous for treating genetic diseases caused by known mutations....
Continue Reading
Since the approval of the first siRNA drug in 2018, oligonucleotide therapeutics have rapidly emerged as a promising drug modality. ...
Continue Reading
Antisense oligonucleotides (ASOs) are single-stranded, synthetic chains of DNA or RNA designed to bind to specific RNA sequences through complementary...
Continue Reading
siRNA holds great promise as a therapeutic modality due to its high specificity, developability, and sustained efficacy. However, its application...
Continue Reading
OncoWuXi Express will continue to keep you informed about updates to our online pharmacology model database (OncoWuXi Database), as well...
Continue Reading
Epilepsy is one of the most common neurological disorders, and cell therapy is a promising area of research that has...
Continue Reading